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Abstract
We have developed the first immature large animal translational treatment trial of a pharmacologic 
intervention for traumatic brain injury (TBI) in children. The preclinical trial design includes 
multiple doses of the intervention in two different injury types (focal and diffuse) to bracket the 
range seen in clinical injury and uses two post-TBI delays to drug administration. Cyclosporin A 
(CsA) was used as a case study in our first implementation of the platform because of its success 
in multiple preclinical adult rodent TBI models and its current use in children for other 
indications. Tier 1 of the therapy development platform assessed the short-term treatment efficacy 
after 24 h of agent administration. Positive responses to treatment were compared with injured 
controls using an objective effect threshold established prior to the study. Effective CsA doses 
were identified to study in Tier 2. In the Tier 2 paradigm, agent is administered in a porcine 
intensive care unit utilizing neurological monitoring and clinically relevant management 
strategies, and intervention efficacy is defined as improvement in longer term behavioral 
endpoints above untreated injured animals. In summary, this innovative large animal preclinical 
study design can be applied to future evaluations of other agents that promote recovery or repair 
after TBI.
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INTRODUCTION
Head injury is the leading cause of death and disability in children (38), and unfortunately 
there are only general management guidelines (3). While only a modest number of pediatric 
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clinical trials for traumatic brain injury (TBI) have been conducted (1, 39, 42, 61, 66, 93), 
nearly all pediatric trials and over 100 adult TBI trials (9, 14, 56, 71) have failed to show 
significant neuroprotective benefits of any pharmacologic therapy.
While general care principles have improved outcomes, specific neuroprotective 
interventions are extremely limited. The heterogeneity of TBI, with distinct 
pathophysiologies and mechanisms associated with contusions, hemorrhages and diffuse 
axonal injuries, added to a panoply of variable host factors, likely contributes to the 
recurrent failure of large head injury treatment trials (60, 74). In children, the immature 
brain response to each type of TBI changes rapidly during development from infancy 
through adolescence (7, 20, 22, 68). Therefore, the development of head injury therapies for 
acute brain injury in children requires appropriate immature animal models in which to test 
potential treatments. Rodents are limited as models for human children because of marked 
differences in maturation, morphology and injury mechanisms (17). Therefore, treatments 
developed in adult rodents might be ineffective, or even contraindicated, in human children.
Motivated by the need for appropriate immature animal models, our collaborating 
laboratories have developed, well-characterized and thoroughly tested immature swine 
models for TBI research for more than 15 years (20, 21, 24, 29, 51, 59, 68, 69, 77, 81). 
These models mimic the spectrum of TBI observed in infants and children. The purely 
inertial (nonimpact) rotation model creates diffuse axonal injury and subarachnoid 
hemorrhage, and the purely focal model creates a localized cortical and subcortical 
contusion (Figure 1). By using both models, we have characterized the response of the 
immature brain at the two endpoints of the focal-to-diffuse and cortical surface to axonal 
white matter injury spectrum. To characterize changing injury responses in the maturing 
brain, we have studied different developmental stages, infancy through adolescence, in both 
piglet models. From these studies, we have determined that the 1-month age (“toddler”) 
piglet has unique characteristics that reflect pathophysiology similar to the preschool and 
early childhood stage in human children. At this age, cerebral blood flow (CBF) is maximal, 
brain swelling is the most pronounced, and other injury responses are similar to the unique 
findings seen in young human children (19, 20, 23).
We have designed an innovative, state-of-the-art preclinical study platform to create a 
translational bridge between basic science discoveries in the rodent and randomized control 
trials for TBI in children. Our preclinical study was led by a collaborative team of pediatric 
TBI experts able to measure the pharmacokinetics (PK) and the short- and long-term 
pharmacodynamic response to treatment for TBI. To duplicate the human clinical setting, 
the platform incorporates the best contemporary pediatric neurocritical care management 
and monitoring strategies to enhance translation to clinical trials. Using our well-
characterized, reproducible and clinically relevant immature porcine TBI models, we 
employed well-developed assessments of physiologic, biochemical and cognitive/behavioral 
outcomes that we believe surpass rodent models for their fidelity to children to determine 
the optimal evidence-based dosing strategy for a future large randomized controlled trial for 
treatments in children with TBI.
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Because mitochondria play a critical role in many primary and secondary pathologic 
pathways in TBI, cyclosporin A (CsA), which inhibits opening of the mitochondrial 
permeability transition pore, was used as a case study in our first implementation of the 
platform. Because of its safety profile in humans, pleiotropic effects and success in multiple 
preclinical adult rodent TBI models, CsA was selected for its multifaceted potential as an 
effective therapy for pediatric TBI. Because CsA was also off-patent and already in use in 
children for other indications, the results of the preclinical therapy development plan could 
be translated rapidly and inexpensively to clinical trial.
METHODS
Animal model selection
We have used our established immature porcine TBI models, controlled cortical impact 
(CCI) and rapid nonimpact rotation (RNR), to produce the spectrum of pathophysiology 
seen in mild to severe TBI in the child, from infancy to early adolescence. The CCI (Figure 
1) model utilizes a skull-mounted, spring-loaded blunt indentation device to create a rapid (4
ms) displacement of the cortical surface, producing a focal cortical contusion, with 
underlying white matter damage, decreased CBF and somatosensory dysfunction (19–21). 
This model was designed to produce a specific injury type, focal contusion, which is one of 
the most common types of brain injury in children and results most often from falls, 
recreational and sports injuries, and vehicular trauma (34, 46, 82). Because the displacement 
of the cortex is coupled to the skull, this model produces no inertial motion of the head 
itself, and in this way embodies a purely focal injury mechanism. The model creates a well-
defined cortical and subcortical contusion with variable hemorrhage which evolves over 
time, is associated with regional brain swelling and changes in blood flow, and can be 
measured by histology or imaging. The contusion is placed in the rostral gyrus, which is the 
somatosensory cortex subserving snout sensation. The injury is not associated with 
immediate changes in consciousness or gross motor deficits. At the other end of the injury 
spectrum, to create a purely inertial injury, the RNR model produces a high magnitude 
acceleration/deceleration, similar to that experienced in motor vehicle or high velocity 
trauma, but with no impact event, and utilizes a single rapid (12–20 ms), sagittal head 
rotation (Figure 1). This injury mechanism produces unconsciousness, sustained cognitive 
dysfunction, bilateral diffuse axonal and hemorrhagic injury; and marked decreases in global 
CBF, brain tissue oxygen content (PbtO2) and alterations in mitochondrial function (24, 29, 
68). Our goal was to inform a clinical study with injury-specific optimal dosing strategies by 
evaluating treatment effectiveness over the spectrum of injury types.
Based on our prior studies of brain development and age-dependent injury responses, the 4-
week-old piglet is similar to human children at the toddler/preschool age (17, 18, 20, 23, 
57). Age-specific responses are attributable to maturational differences in brain mass, 
stiffness, deformation tolerance and biological responses. The toddler age in the child was 
chosen for our first test of this large animal model platform for therapeutic development 
because it is an age with physiologically important and maximal developmental differences 
in myelination, apoptotic pathways, glutamatergic receptor mechanisms, synaptogenesis and 
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CBF responses compared with adults. The toddler piglet mimics the range of measureable 
post-TBI morbidity seen in the human toddler and young child.
Therapy development plan overview
Recent workshops of the TBI and stroke scientific communities have examined why agents 
with preclinical therapeutic efficacy have failed to translate to clinical success (15, 27, 36, 
50). They concluded that agents should be tested in multiple species using clinically relevant 
outcomes, short-term and long-term endpoints, histological and functional metrics, and 
include clinical management strategies (45). We conducted our therapy development studies 
across multiple laboratories, while including current pediatric TBI critical care management 
protocols, clinically relevant physiological monitoring, and realistic injury-to-treatment 
intervals of 1 and 6 h after TBI, to mimic urban and rural time to implantation of therapy. 
Treatments were administered intravenously (IV) for 24 h via an ambulatory wireless 
programmable infusion pump, delivering a loading dose followed by continuous infusion to 
achieve target concentrations rapidly and to sustain exposure, similar to current clinical 
studies for adult TBI (54). The platform employs a two-tiered funnel approach: focusing 
first on multiple short-term (24 h) endpoints—histological and cellular bioenergetic 
measures—to identify dosing strategies with a reproducible, robust efficacy, followed by 
studies evaluating sustained cognitive benefits. Importantly, the platform includes obtaining 
microdialysate samples and blood for serum biomarkers, currently unconfirmed clinical 
intensive care readouts in children, and in future secondary analyses we plan to correlate 
them with direct measures (mitochondrial function and pathology) and neurofunctional 
behavior. These analyses, which are an important feature of our preclinical development and 
optimization plan, will accelerate the translation to a rational clinical trial design, informing 
the monitoring and management strategy, as well as inclusion criteria. Finally, although we 
recognized the potential for inflation of type I error through the multiple experiments 
utilized in the platform, the use of efficient factorial design in combination with the overall 
sequenced study design was created to optimize identification of promising treatments in an 
important clinical area with no effective pharmacologic interventions. In summary, this 
state-of-the-art, innovative preclinical study design will be applied to future evaluations of 
other agents that promote recovery or repair after TBI, other ages, combination therapies and 
other types of TBI.
In the first tier of our Therapy Development Plan, we evaluated the tolerability and efficacy 
of the therapeutic agent to identify two promising doses for each injury type (diffuse, focal) 
and post-TBI treatment start times (1 and 6 h) based on terminal endpoints of 
neuroprotective effectiveness at 24 h. In the second tier, the optimum dose for each injury 
type and start time with the best 6-day cognitive outcomes is identified. In Tier 1, for each 
start time and injury type, both the most effective dose and the lowest dose that achieve a 
significant effect advance to Tier 2 for further study. In Tier 2, not yet conducted, these two 
doses for each start time and injury type are assessed for their efficacy in neurocognitive 
outcomes, measured 6 days after injury, to identify the optimal dosing strategy to evaluate in 
clinical trials. Later studies will identify PK, toxicology responses and sex-specific cognitive 
recoveries to the therapeutic dosing strategy and injury type that showed the best cognitive 
recovery in Tier 2.
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As a proof-of-translation study, we used the immature large animal model platform as a 
preclinical study to evaluate the effectiveness of agents with a demonstrated track record of 
efficacy in adult rodent focal neural injury models and an established safety profile in 
children. Additional considerations may also be that the agent is in therapeutic use or 
clinical trials for other indications in adults and children, enhancing rapid translation to a 
clinical trial. We selected CsA as our case study, and our rationale for agent selection is 
discussed in the next section.
Agent selection
TBI processes, including contusion, diffuse or focal axonal injury, hematomas, and 
subarachnoid hemorrhage (1, 2, 58, 74), can initiate ischemia, edema, inflammation, tissue 
shifts and brain herniation (9). Subsequent cellular and molecular responses progress over 
minutes, hours and days to mediate progressive cellular damage (50, 52, 65, 67, 76, 95), 
decreased CBF and mitochondrial disturbances (35, 52, 65, 80, 91, 97). A growing body of 
literature suggests that mitochondria play a key role in many pathologic pathways in 
neurodegenerative disorders, focal/global ischemia and trauma (48, 73, 75). Mitochondrial 
dysfunction leads to energy imbalance, ionic imbalance, release of cytochrome c, 
proapoptotic events, mitochondrial swelling and reduced brain ATP levels (86).
Following pediatric TBI, mitochondrial dysfunction is involved in excitotoxicity, oxidative 
stress, metabolic perturbations and, ultimately, cell death (73). It is difficult to extrapolate 
adult TBI data to pediatric models because critical mitochondrial characteristics such as the 
number and density of complexes of the electron transfer chain, antioxidant enzyme activity 
and content, and lipid content are very different between young and adult animals (8, 16). 
To our knowledge, no investigators have tested potential mitochondria-targeted 
neuroprotective therapeutic strategies in a large animal model of pediatric TBI.
CsA inhibits progressive mitochondrial dysfunction by stabilizing the mitochondrial 
transition pore (87). Preclinical TBI and ischemia CsA studies (mostly in rodents) have 
demonstrated neuroprotection using immunohistochemistry, isolated mitochondrial 
preparations and behavioral tests (6, 25, 28, 30, 37, 47, 78, 83, 87). The advantages of CsA 
are that it is FDA approved, off-patent, inexpensive and thought to have well-described 
safety and dosing profiles. In January 2015, there were 109 open clinical trials using CsA in 
children for indications other than brain injury. In a TBI Phase I clinical trial in adults, CsA 
satisfied a broad range of safety parameters (54), but no Phase II or III trial is in progress 
(53). Although CsA has delayed brain penetration and its chronic usage adversely impacts 
the immune system, we may avoid similar immunological concerns when CsA is limited to a 
short period, such as for acute TBI treatment. In summary, because of its safety profile in 
humans, multimodal pharmacological effects, and success in multiple preclinical rodent 
models of brain injury, CsA has potential as a therapeutic agent for neuroprotection in 
children after TBI. We hypothesized that CsA would inhibit mitochondrial dysfunction and 
decrease axonal and neuronal injury within 24 h after head trauma, and would promote 
longer term neurological functional recovery. Our objective was to obtain data on the PK 
and pharmacodynamics of CsA in two established immature large animal preclinical models 
to provide evidence-based dosing guidance for a future large randomized controlled trial for 
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CsA in children. Our central hypothesis is that safe, therapeutic concentrations of CsA could 
improve outcomes for children who have sustained TBI.
Dosing rationale—allometric scaling across species
Tier 1 dose selection is based on published rodent neuro-injury (6, 55, 87), our previous data 
in the infant piglet (44), published dosing guidelines, and Phase I–IV clinical trials. Rather 
than scaling the dose across species normalizing by body weight, more recent PK literature 
advocates the extrapolation of rat dose to pig and human doses be performed through 
normalization to body surface area using the Km factor and the following formula: dose for 
animal x in mg/kg equals the dose in animal y in mg/kg times (Kmy/Kmx) (70), where the 
estimated Km for the rat, 4-week-old piglet, human child and adult are 6, 20, 25 and 37, 
respectively. First, CsA was studied in an adult rat model of focal TBI, and a U-shaped 
dose-response was observed (6, 55, 87), such that the most beneficial dose was determined 
to be 20 mg/kg/day divided in two 10 mg/kg doses (87). Using relevant allometric Km, this 
optimal rat dose translates into 6 mg/kg/day in the pig and 3.3 mg/kg day in the human 
adult. Second, CsA is being used clinically in the human in doses between 5 and 21 
mg/kg/day (32, 49, 54), which translate into “safe” doses of 9.25 and 39 mg/kg/ day in the 
pig and 30 and 126 mg/kg/day in the rat. Third, in the infant piglet, we have conducted pilot 
studies (N = 4–5/group) and found that an IV bolus of CsA (20 mg/kg) given 5 min and 
again at 12 h after RNR TBI (totaling 40 mg/kg/day) markedly reduced lesion volume and 
lactate-pyruvate ratios 24 h after TBI, with increased CBF and mitochondrial respiratory 
control ratio (RCR) in hippocampus, olfactory, cortex and cerebellum, compared with 
saline-treated injured piglets. Given the U-shaped pharmacodynamics of CsA (85), the 
toxicity data from humans, and effective doses in rat and piglet, we investigated four CsA 
doses higher and lower than our infant piglet studies: 10, 20, 40 and 60 mg/kg/day for Tier 1 
optimization studies, given toxicity data in humans and doses deemed effective in the rat and 
piglet. Based upon human TBI clinical trials, rodent CCI and porcine RNR studies, 
treatment duration was 24 h for all tiers. The half-life of CsA is long, approximately 18 h in 
newborn pigs and 7 h in mature pigs (92), and steady state exposure cannot be reached 
during a 24-h treatment duration. A rapid loading dose can achieve therapeutic 
concentrations faster, but plasma CsA levels may exceed tolerable concentrations (26, 84). 
Renal tolerance limits in the pig are 9 mg/kg IV over 1 h (13), but higher loading doses have 
not been studied and may be tolerated. In summary, based on CsA half-life, published CsA 
pig clearance rates and tolerance, and the current human clinical trials employing continuous 
IV infusion, the 24-h dose strategy was to be divided into a 1-h IV loading infusion to reach 
target concentrations rapidly, with the remainder delivered in a 23-h continuous IV infusion 
for sustained exposure, with a ratio (in mg/kg) of 0.32 between load and infusion doses. 
Because the 40 and 60 mg/kg/day dose will exceed 9 mg/kg in the loading period, and no 
data are available for piglets, future toxicology studies should be performed should those 
higher doses prove effective.
Agent-specific evaluation metrics for screening in Tier 1
Tier 1 was the short-term (24-h) evaluation of the CsA dose-response of traumatic brain-
injured piglets. Treatment efficacy was evaluated using two terminal endpoints, 
neuropathology and mitochondrial function, in animals sacrificed at 24 h after treatment was 
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initiated. Our rationale for using mitochondrial function, specifically maximal coupled 
respiration (RCR), as a criterion for positive outcome effectiveness is that previous studies 
demonstrated that RCR decreases within hours after TBI, remains impaired days later, and 
its early rescue with mitochondrial protectant CsA correlates with cognitive benefits at 7 
days after injury (11, 55, 79). In infant piglets (3–5 days old) treated with 40 mg/kg/day CsA 
IV divided into two injections post-RNR, reductions in RCR were inhibited and maintained 
at sham levels (44). Similarly, we selected lesion volume (Vinj) at 24 h post-TBI as a second 
positive outcome metric based upon prior studies which demonstrated that after CCI in the 
piglet brain lesion volume is near maximal around 24 h after injury (19), and that injured 
volume was reduced by 42% in the RNR-injured infant animals treated with 40 mg/kg/day 
CsA IV (44).
When we designed the Tier 1 study as a screening paradigm, we understood that the 
variability of the underlying condition in genetically heterogeneous subjects would require 
very large animal group sizes (and prohibitively high costs) to identify effect magnitude and 
formulate a dose–response curve. Thus, cost considerations restricted our study design, 
making comparisons of size of effect across doses untenable. Therefore, using clinical trials 
with multiple “success metrics” as our guide, in our analysis we defined positive outcome 
“thresholds” for pathology and mitochondrial function, and enhanced our statistical power 
by combining the results from these two sets of animals by determining a total “positive 
outcome” rate. Consequently, Tier 1 was designed as a screening paradigm to select 
promising doses for Tier 2 based on the combination of two metrics. As such, the efficacy 
analysis is not based upon the absolute treatment effect size (lesion size or mitochondrial 
function); instead, the analysis is based upon achievement of a clinically significant greater 
number of “positive outcomes” with treatment compared with untreated injured subjects. 
The definitions of “clinically significant” alterations to mitochondrial function and 
neuropathology were determined by pilot series to obtain thresholds prior to evaluation of 
the experimental data. Based on criteria discussed in the next two sections, each subject was 
classified as either a “neuropathology lesion volume positive outcome” or “mitochondrial 
function positive outcome.” Efficacy was defined when ≥30% more of the N = 20 animals in 
a CsA dose/time/model group had a combined positive outcome (based upon mitochondrial 
function and neuro-pathology) compared with injured time/model controls receiving only 
saline. This is a very ambitious threshold to identify promising therapies as a consequence of 
budgetary constraints dictating small study cohort sizes.
Because it is postulated that the optimal dose may vary with injury-to-treatment interval and 
between focal and diffuse injuries, each post-injury start time and each injury type were 
analyzed independently (four groups: 1-h delay to treatment initiation CCI, 6-h CCI, 1-h 
RNR, 6-h RNR). For each group, all doses that met the efficacy criteria were eligible to 
move forward to Tier 2 experiments to determine longer term neurofunctional outcomes. 
However, the platform was designed so that if multiple doses for a post-injury start time 
showed efficacy at the end of Tier 1, a maximum of two doses for each start time/injury-type 
group would move forward to Tier 2, the dose with the highest success rate (“greatest 
neuroprotection”) and the lowest dose that meets the success criterion for demonstrating a 
successful neuroprotective effect, to potentially limit the side-effect profile. Furthermore, if 
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we found a tie for two doses with the highest success rate at an administration time for a 
given model, we would select the dose that has the highest magnitude of positive outcome. 
The maximum number of dose-model-treatment time combinations moving forward from 
Tier 1 to Tier 2 would be 8 (2 doses × 2 models × 2 delays to treatment) plus normative 
controls, a dramatic reduction from the total number across all of the dosing groups studied 
in Tier 1. This strategy was chosen as a practical way to limit the trial animal and resource 
utilization and expense.
Pathology threshold for positive outcome
To judge effectiveness in Tier 1 screening, we had to determine a threshold for each 
surrogate outcome measure (pathology and mitochondrial energetics) that would be used to 
designate a subject as showing a likely effect of CsA. We defined a subject classified as 
showing a clinically significant “positive outcome” for the pathology effectiveness metric as 
an animal with a reduction in lesion volume that is large compared with the distribution 
found in the saline-treated (vehicle) animals with the same injury type. To accomplish this, 
we determined the mean and standard deviation of the lesion volumes in a relevant injury-
matched vehicle group (CCI or RNR) generated prospectively prior to the Tier 1 
experiments and established a threshold of 0.85 times the standard deviation (0.85*stdev) 
less than this vehicle group mean. Because of small but potentially meaningful differences 
in the specific CCI devices and the rotational velocities used in the injuries between the first 
and second years of the Tier 1 study, we determined a pathology threshold that was unique 
to each year. Therefore, each treated (and vehicle) animal was evaluated against the relevant 
“positive outcome” threshold to determine pathology positive outcome rates for every dose/
time/model group. Importantly, this bar was more demanding (larger injury reduction 
required to be considered a “positive outcome”) when the injury volume was more variable 
in our vehicle control group. In fact, this objectively derived pathology threshold established 
that a reduction in lesion volume of 21%–58% was required for a CsA-treated animal to be 
considered a positive outcome (across all TBI models, times and years), averaging 25% in 
the RNR groups and 50% in the CCI groups—a dramatic reduction in pathology. The total 
number of “Pathology positive outcomes” is provided in the Results (Table 2). In short, for 
each model, defining the threshold for a positive outcome as the mean +0.85*stdev of the 
untreated injured group set the “positive outcome” rate at 20% of the untreated injured 
vehicle controls. We found that the treatment groups had positive outcome rates of 0%–
60%.
Mitochondrial threshold for positive outcome
For diffuse brain injury, we defined the mitochondrial functional threshold for positive 
outcome as the RCR measured in isolated mitochondria greater or equal to 5 (after 
combining results from the cortex and hippocampal regions) based upon our own prior data 
in the RNR model (44). Historically, a single RCR value is rarely used to define an injury 
threshold for focal TBI models. Rather, RCR in the ipsilateral injured side is typically 
compared with a benchmark value, for example, RCR in the contralateral side in the same 
animal, ipsilateral side in sham controls, or the ipsilateral side in treated injured animals. 
Moreover, our extensive review of the animal literature on this specific aspect of 
mitochondrial functional assessment reveals that the RCR on the ipsilateral injured side can 
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vary considerably, lab to lab, justifying the use of comparative benchmark ratios for focal 
brain inju ries, usually the contralateral side in the same animal, thus generating an RCR 
ratio. We generated a separate set of (N = 5) untreated CCI piglets to define the positive 
outcome threshold for the mitochondrial function metric. Not surprisingly, the mean 
ipsilateral : contralateral RCR ratio of this untreated injured piglet group (mean ± stdev, 0.55 
± 0.33) was significantly lower than those from N = 7 uninjured shams (1.04 ± 0.46, P = 
0.03). As with the pathology positive outcome threshold, we used the mean and standard 
deviation (stdev) of our untreated CCI group to define an objective threshold for a positive 
outcome as 0.85stdev greater than the mean untreated value. Specifically, a positive 
outcome was an RCR ipsilateral/contralateral ratio value ≥0.83, derived as the mean RCR 
ratio of untreated injured controls plus 0.85 times the standard deviation, or 0.55 + (0.85)
(0.33) = 0.83.
Tier 1 studies were conducted over 2 years. In year 2, for the second half of the Tier 1 
studies, we took advantage of rapidly evolving technological developments in mitochondrial 
assessment to provide a more robust evaluation of mitochondrial function. We made three 
improvements in our measurements of mitochondrial respiration. First, we transitioned from 
tissue mitochondrial isolation techniques to new protocols developed to utilize tissue 
homogenates for mitochondrial respiration. Homogenates potentially have several 
advantages over isolated mitochondria preparations: reduced disruption of intracellular and 
intercellular signaling pathways (94), preservation of mitochondrial structure and function 
(63, 64), and decreased mitochondria population loss, which may be >60% with isolation 
techniques (62). Thus, homogenates may provide a more relevant and reliable assessment of 
in vivo function. As a second technological improvement in year 2, we upgraded our 
traditional Clark-type oxygen electrode (Hansatech Instruments, Norfolk, UK) that measures 
oxygen consumption in nmols to a more sensitive instrument (Oxygraph-2K, OROBOROS 
Instruments, Innsbruck, Austria) that measures oxygen consumption in pmol, providing a 
more consistent and nuanced readout of mitochondrial respiration. Third, we upgraded our 
respiration protocol by adding the substrate succinate to allow us to measure oxidative 
phosphorylation via integrated convergent complex I and II electron flow (33), whereas our 
year 1 standard respiration protocol only utilized NADH-linked substrates (pyruvate + 
malate).
We therefore generated an additional set of benchmark untreated sham (N = 20) and injured 
(CCI or RNR N = 20) animals. We confirmed that RCR ≤5 still distinguished RNR-injured 
animals from shams, but while the ipsilateral to contralateral ratio of total oxidative 
phosphorylation was similar after these technological enhancements, the ratio measurement 
now had less variability. Specifically, the untreated CCI total oxidative phosphorylation 
ipsilateral to contralateral ratio was 0.61 ± 0.15, yielding a positive outcome defined as a 
ratio ≥0.73. In parallel manner to the evaluation of positive outcomes for pathology, CCI 
animals in year 1 were evaluated against the year 1 threshold, and those in year 2 were 
evaluated against the year 2 CCI threshold. The total number of “Mitochondrial function 
positive outcomes” is provided in Table 2. For each model, about 35% of the vehicle 
controls met the criteria to be designated as spontaneous “positive outcomes,” while the 
treatment groups had mitochondrial functional positive outcome rates of 30%–70%.
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Statistical considerations
Power calculations were performed to determine the minimal difference that can be detected 
with the proposed sample size of 20/group in Tier 1 and 30/group in Tier 2. We assume one-
sided α = 0.05 and 80% power; one-sided tests were chosen to identify potentially 
efficacious strategies. For binary outcomes such as positive outcome rates, Table 1 shows 
the detectable rate differences, based on Fisher's exact test, for various underlying control 
rates. The maximum width of (two-sided) 95% confidence intervals is also shown. For 
continuous outcomes, such as mean RCR values, the detectable difference is presented as 
the effect size (Wilcoxon rank-sum test); the width of a 95% confidence interval is also 
shown. Based on our previous data (44), we expected the spontaneous positive outcome rate 
in controls to be approximately 10%, and selected our group sizes accordingly, using N = 20 
evaluable animals per dose/time/model group for Tier 1 (24-h outcomes).
Prior to formal statistical analysis of outcomes, potential data errors or outliers and 
necessary variable transformations were examined. Standard descriptive statistics including 
means, standard deviations and proportions were computed for all measures. Confidence 
intervals (95%) were produced for all summary statistics. In Tier 2, exact versions of 
nonparametric tests were to be used for k-group comparisons, including Wilcoxon and 
Kruskal–Wallis tests for continuous measures and Fisher's exact or McNemar's tests for 
proportions. Linear regression was also planned to evaluate associations among secondary 
endpoints obtained in Tier 2. The dependent variables will be the primary endpoints from 
Tier 1 (mitochondrial function and injury volume) and Tier 2 (cognition, balance, 
actigraphy). Predictor variables will be the potential physio-markers (point-of-care metrics 
such as microdialysis and serum biomarkers). It is recognized that the large number of 
simultaneous experiments raises the possibility of inflation of type I error through these 
future multiple comparisons. This would be carefully considered in the evaluation of all 
results.
Tier 1 efficacy was defined as having ≥30% more of the N = 20 animals in a CsA dose/time/
model group with a combined positive outcome (based upon mitochondrial function and 
neuropathology) compared with injured time/model controls receiving only saline (Agent-
specific evaluation metrics for screening in Tier 1). The specific numbers and calculations 
used to determine positive outcome rate in this study are designed to overcome the inherent 
limitations of using small sample sizes to estimate the response of a population. Essentially, 
because of the significant expense of large animal work, statistical approaches must be used 
to determine true potential or underlying promise from a small number of subjects. In the 
Results (Tier 1 positive outcome rates), we report that we have a fairly consistent 
spontaneous “positive outcome” rate of 30%–35% in our vehicle control animals because 
even after mild-to-moderate rapid head rotation or cortical impact, approximately one-third 
of the animals have modest mitochondrial or pathological damage. Our effectiveness 
evaluation dictates that for a dose to move on to Tier 2, a treated group must have an 
underlying “positive outcome” rate of 60%–65%, respectively. Statistically, the larger the 
group one samples, the more likely the group estimates the true or underlying response of a 
population. For smaller groups, we must consider the errors associated with our uncertainty 
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that the results reflect the true or underlying positive outcome rate of the injured animal 
population.
If we fail to consider the response rate measurement uncertainty in our preclinical study with 
20 animals in each of the four dose-time study arms, we would reject any dose that had less 
than 13 animals (which is 65% of N = 20) “above the positive outcome bar” in each group. 
However, because our measurement of a “positive outcome” rate is only an approximation 
of the true population response with this small sample size, we would have a 40% 
probability of excluding a dose with an inherent positive outcome rate that met our criteria 
(40% beta error). This 40% probability of excluding a dose with an underlying response rate 
that actually met our effectiveness evaluation criteria is a risk of rejecting a successful dose 
that far exceeds the standard for screening for a promising agent in the pharmaceutical 
industry (10). Instead, we set our beta error risk at the pharmaceutical industry standard for 
single-arm randomized clinical trials (10), accepting a 5% chance of excluding a dose with 
an inherent positive outcome rate that met our effectiveness evaluation criteria of moving a 
dose forward if its underlying positive outcome rate ≥ 60%–65%. More details are provided 
in Tier 1 positive outcome rates.
Tier 1 therapy development study design
Only injured animals were evaluated in Tier 1. Injured animals received either saline vehicle 
(0 mg/kg) or CsA treatment at 1 of four different doses (10, 20, 40, 60 mg/kg) delivered 
using a bolus followed by a continuous infusion for 24 h (five doses). Treatment was 
initiated 1 h after injury or 6 h after injury (two timepoints) and extended for 24 h. Both 
brain injury types were studied: RNR diffuse injury and CCI focal injury. Taken together, 5 
doses × 2 timepoints × 2 injury models yields 20 groups. Each of these 20 dose-time-model 
groups has two outcome measures evaluated (N = 10 animals for neuropathology and N = 
10 for mitochondrial function). Because one of our central hypotheses was that mitigation of 
mitochondrial dysfunction leads to improved neuropathology, our effectiveness evaluation 
dictated that the success of a dose must be evaluated by combining treatment-associated 
improvements in mitochondrial function and pathology (N = 20 per treated group). A second 
central hypothesis is that the dose of CsA may depend on the delay to initiation of treatment 
and the injury type. Thus, in our study design, analysis plan and effectiveness evaluation, the 
five doses were clustered together into four single-arm randomized preclinical trials for 
CsA, one for each of the four start time-model combinations. As mentioned earlier, 
untreated injured controls were added in year 2. To reduce costs, we assumed untreated 
injured controls were similar regardless of the delay to saline administration, and we 
reduced the number of 6-h controls, as shown in Tables 2 and 3. Taken together, the final 
Tier 1 planned enrollment was N = 440 injured piglets.
Piglets (N = 440 females, 4 weeks old) were anesthetized, instrumented and monitored as 
described previously (44), and buprenorphine (0.02 mg/kg IM) was administered for 
analgesia. An IV with low absorbance tubing was inserted into the cephalic vein, and 
tunneled subcutaneously to the mid-scapula to an ambulatory infusion pump (3D BT mini 
infusion, Strategic Applications Inc., Infusion Technologies, Lake Villa, IL, USA), to 
administer CsA or saline, and to withdraw pre- and 24-h post-injury blood samples for 
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serum protein biomarker analysis. Animals were assigned to receive CCI or RNR injury. As 
mentioned earlier, for CCI, a skull-mounted, spring-loaded blunt indentation device was 
used to deform approximately 1 cm3 of the cortical rostral gyrus rapidly (4 ms), with a 
typical lesion volume (Vinj) of 8% of the hemisphere or 4% of the cerebrum (20). For RNR, 
the snout was secured, and the head rotated 60–70° rapidly (12–20 ms) in the sagittal plane 
without impact (68). Within each injury group, animals were assigned to a CsA post-TBI 
start time of 1 or 6 h, and randomized to one of the four CsA dose groups (10, 20, 40, 60 
mg/kg/day) or saline. Treatment was administered intravenously according to the dosing 
schedule described above. Post-injury, animals were monitored until fully recovered from 
anesthesia and observed until they demonstrated vocalization (without squealing), steady 
ambulation, no aggression or avoidance behavior, no piloerection and presence of proper 
feeding, and then returned to the animal housing unit after the initial IV loading dose, with 
continuation of the infusion delivered in the housing facility. Typically, during recovery, 
animals initially exhibited purposeless behavior, had poorly coordinated motor function and 
were unusually lethargic or easily agitated, similar to mild-to-moderate TBI in the child.
After 24 h of CsA treatment, animals were anesthetized, and a final blood sample was 
obtained. Subjects were sacrificed, and either fresh brain tissue was collected to determine 
the mitochondrial function (N = 10 per group), or brains were perfused transcardially with 
unbuffered formalin to quantify injury volume (Vinj) via histology (N = 10 per group).
For mitochondrial isolation, the brain was exposed, and specimens were removed rapidly 
after euthanasia. From RNR animals, bilateral 3–5 mL regions of cortex and hippocampus 
were removed. From CCI animals, a 2-cm-per-side cube of cortex and underlying white 
matter centered at the CCI impact site was removed and necrotic tissue was removed, and a 
mirrored sample from the contralateral side was resected. From the fresh tissue in year 1 of 
Tier 1, mitochondria were isolated rapidly (88), and RCR (RCR = State 3 divided by State 
4) was determined (72). In year 2, the same regions were homogenized and a serial
substrate, uncoupler, inhibitor titration (SUIT) protocol previously used for rodent brain 
tissue (43) was optimized for the piglet, and maximal coupled phosphorylating respiration 
capacity via convergent input through complexes I and II (OXPHOSCI + CII) was determined 
and normalized by LEAK respiration or State 40.
For histology, after perfusion, brains were removed and immersed in fixative. Brains were 
cut in serial 3-mm coronal sections, photographed for determining total cerebral volume, 
and examined for gross pathology to document subdural and subarachnoid hemorrhages and 
surface contusions. Finally, 6-μm-thick slices from each 3 -mm coronal section were stained 
with hematoxylin and eosin (H&E) and β-APP, and examined by the neuropathologist on 
our team (CS, blinded to experimental group) who reviewed every field of every slide 
microscopically. Documented major pathology includes hemorrhages, established infarcts 
(changes in staining intensity) and ischemic neurons (cell shrinkage and eosinophilia). 
Axonal injury was detected via β-APP immunohistochemistry to identify disruption of 
axonal flow and regions of ischemic axonal injury. The distribution of axonal and neuronal 
injury was annotated on the digital photographs for each animal (31, 96). To quantify the 
extent of brain injury, the brain periphery of every 3-mm section was traced to determine the 
brain area (Photoshop, Adobe Systems Incorporated, San Jose, CA, USA). The locations of 
Margulies et al. Page 12
Brain Pathol. Author manuscript; available in PMC 2016 May 01.
white matter damage, infarct and ischemia were traced in each slice using the same 
procedure to determine injured brain area. Lesion volume (Vinj) was defined as total injured 
area (axonal injury plus infarct/ischemic lesions) divided by total slice area.
Tier 2 study design
Tier 2 was designed to mimic the clinical care setting, and prospective criteria for 
effectiveness have been identified, but studies have not been conducted to date. In Tier 2, we 
plan to evaluate 6-day post-TBI neurofunctional outcome metrics for up to two doses for 
each model/time group meeting our effectiveness criteria for Tier 1. The results of treated 
injured animals will be compared with injured piglets administered vehicle (N = 30/group), 
in naïve shams (N = 12), and CCI and RNR uninjured shams with an intensive care unit 
(ICU) experience (N = 12/group). The most effective CsA treatment-model combinations 
will then be tested in males to assess for any gender effects and serum processed for CsA 
concentrations to translate porcine PK to humans using a computational model. Focal and 
diffuse injuries will be created as in Tier 1. As in Tier 1, treatment will be an IV load 
followed by continuous infusion, with treatment duration of 24 h. Saline-only treatment of 
injured animals will be initiated 1 h post-injury. During the first 24 h after injury or sham 
anesthesia, animals will receive continuous neurointensive care monitoring, including CBF, 
intracranial pressure (ICP), mean arterial pressure (MAP) and PbtO2, as well as IV fluids 
and respiratory support. We will use a clinical-based protocol to ensure consistent cerebral 
perfusion pressure (CPP) and ICP management (9) (see flowchart provided in Figure 2). 
During this 24-h period, serial blood and microdialysis samples will be obtained to measure 
PK, biomarkers and lactate/pyruvate ratio (LPR) time courses. The biomarkers and LPR are 
unconfirmed intensive care measures that will be used in a secondary analysis to guide 
clinical trial design. These serum, microdialysis and physiological biomarkers are not 
included in the effectiveness criteria; rather, they will be evaluated as informative prognostic 
markers of injury severity and recovery.
After the injury has been completed and an unconsciousness time was recorded (reaction 
time post-injury to an interdigital toe pinch), anesthesia will be switched to a continuous 
midazolam (0.1–0.6 mg/kg/h) and fentanyl (50 μg/kg/h) IV infusion for 24 h (Day 0–1) 
while being monitored in the NIH-funded state-of-theart Neurointensive Care and 
Assessment Facility that houses pigs for up to 3 days after TBI with round-the-clock care. 
Cerebral microdialysis probe (CMA 12 PAS elite 4 mm probes, CMA, Torshamnsgatan, 
Sweden), a thermal diffusion CBF probe (Bowman Perfusion Monitor, Hemedex 
Cambridge, MA, USA) and a brain tissue oxygenation electrode with temperature probe 
(Licox, Integra Plainsboro Township, NJ, USA) will be inserted into the frontal lobes of the 
RNR model. In the CCI model, probes will be placed in the ipsilateral frontal lobe. A fiber-
optic ICP monitor (Camino, Integra) will also be placed in the frontal lobe. Mean arterial 
blood pressure will be monitored via a cuff on the forelimb. Cerebral microdialysis samples 
will be collected at 1, 2, 4, 6, 12, 18 and 24 h post-injury at a flow rate of 10 μL/minute 
using 0.9% NaCl as the dialysate. Immediately after collection, samples will be stored at 
−70°C. Levels of lactate and pyruvate will be measured in the dialysate using a 
microdialysis analyzer (ISCUS-flex, M Dialysis, Stockholm, Sweden). Lactate-pyruvate 
ratios will be calculated from their respective values.
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During the 24-h ICU period, piglets will receive continuous neurointensive care monitoring 
(CBF, ICP, MAP, brain tissue oxygenation content), intravenous fluids and respiratory 
support (if necessary), and isotonic intravenous fluids to maintain normovolemia and 
normoglycemia and/or vasopressors to support a CPP ≥40 mmHg and ICP ≤ 20 mmHg, to 
ensure consistent management across groups, and to provide fidelity between current first-
tier clinical practice for acute management of severe TBI in pediatrics (3, 4, 41) and our 
translational platform (see flowchart). All animals that required mechanical ventilation will 
have minute ventilation adjusted to maintain PaCO2 between 35 and 45 mmHg and oxygen 
titrated to avoid hypoxia (5, 12). While intubated, piglets will receive midazolam (0.6 
mg/kg/h) and fentanyl (25–100 mcg/kg/h) infusions for sedation and analgesia, respectively, 
the most common sedation regimen used in human pediatric critical care. Because of the 
indwelling cerebral monitors, all piglets will receive antibiotics (cefazolin, 25 mg/kg, every 
8 h) during the 24-h stay in the ICU.
During this 24-h ICU period, 12 serial blood samples will be removed for CsA concentration 
determination from some of the animals (N = 16/group) in each injured study group using 
low absorbance tubing and syringes. Specifically, eight pigs from each group will undergo 
the following 12-sample PK sampling strategy: pre loading dose, immediately post loading 
dose, and then 0.5, 1.5, 2.5, 4, 6, 9, 13, 17 and 21 h after the start of the infusion and 
immediately prior to end of infusion. Eight pigs from each group will undergo the following 
complementary 12-sample PK sampling strategy: pre loading dose, immediately post 
loading dose, and then 0.5, 1.5, 2, 3, 5, 7, 11, 15 and 19 h after the start of the infusion and 
immediately prior to end of infusion. Serial blood samples will be obtained from the others 
(N = 12/group) and all uninjured groups to measure biomarkers at four timepoints: pre-
injury, and at 8 and 24 h, and 6 days post-injury. The PK and pharmacodynamic data will be 
used to determine optimal porcine CsA exposure, and we will determine if LPR and 
biomarker samples correlate with cognitive outcomes in a secondary analysis.
After 24 h, animals will be weaned from support. The same recovery practice used for our 
24-h survival studies (in Tier 1) will be implemented for the recovery process of this group. 
The animals will be returned to the animal care unit when the following criteria for 
stabilization are met: vocalization without squealing, steady ambulation, no aggression or 
avoidance behavior, no piloerection, and presence of proper feeding/drinking. The animals 
will be allowed to recover for the remainder of the day (Day 1). Any animal not meeting 
these criteria by the end of Day 1 will be sacrificed and excluded from analysis. Upon 
successful recovery, the animals will continue on to participate in post-injury neuro-
functional studies on Days 1–6 post-TBI, as described previously (40, 89, 90).
To demonstrate neurofunctional efficacy, neurofunctional assessments will be performed for 
6 days post-injury. To move forward to consideration for clinical trial, a dose must have a 
statistically significant improvement in at least one neurofunctional metric compared with 
the similarly injured group receiving vehicle. Only fully evaluable treated and vehicle-
administered subjects from the RNR and CCI injuries (30/group) will be considered, and 
performance metrics may vary by the injury model, because we find that the distribution of 
brain injury affects functional outcomes (40). If an effective dose for at least one injury type 
(diffuse RNR or focal CCI) with significant neurofunctional improvement post-injury in 
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female piglets is identified, that dose will be evaluated for one injury model in male piglets 
to identify any sex-related therapeutic differences.
Record keeping methods
To facilitate translation from preclinical studies to investigational new drug application 
submission for a future clinical trial, we developed drug accountability reporting forms and 
a patient record system to provide easy translation to human trials. In addition, all data entry 
forms are in a secure “cloud”-based application (REDCap system, Research Electronic Data 
Capture) to facilitate the multisite data entry (University of Pennsylvania, Massachusetts 
General Hospital and Edinburgh University), with appropriate backup and user edit logging 
time stamps. Furthermore, for each of the four groups defined by injury model (RNR or 
CCI) and time (1 or 6 h post-injury), and each of the outcomes (RCR or pathology), a 
separate randomization schedule was created prospectively. Each schedule used a permuted 
block design with block sizes of six for the 1-h experiments (which included 10 vehicle 
controls) and block sizes of five for the 6-h experiments (five vehicle controls). Allowances 
were made for the replacement of animals that did not complete the experiment and 
additional controls in year 2. The schedules were created in Excel (Microsoft Corportion, 
Redmond, WA, USA) and then locked to electronic editing. These rigorous documentation 
instruments are essential for ease of translation to clinical trials.
RESULTS
For Tier 1, we studied 497 piglets (Table 2) to achieve the target enrollment of 440 injured 
subjects in our preclinical trial. We excluded 57 subjects based upon our prospectively 
defined inclusion/exclusion criteria, including difficulties intubating or placing lines prior to 
injury, prolonged desaturation (>5 minutes at <90% oxygen while breathing room air) after 
injury, failure to maintain normothermia (between 37 and 39°C), failure to reach milestones 
for return of spontaneous breathing and return to the husbandry unit by 5 h post-TBI, and 
amount of agent dispensed from the infusion pump by sacrifice is >15% less than expected. 
Specifically, animals were excluded secondary to technical issues with the intravenous drug 
delivery system (N = 28), failure to achieve post-injury recovery benchmarks for return to 
the husbandry unit (N = 21), and various technical problems pre- or post-injury that 
precluded adherence to the protocol (N = 8).
Tier 1 positive outcome rates
Each of the four start time-model combinations was evaluated as a separate single-arm 
randomized preclinical trial for CsA efficacy. To determine the total positive outcome rate 
for each dose-time-model combination, the numbers of pathology and mitochondrial 
function positive outcomes (as defined in Pathology threshold for positive outcome and 
Mitochondrial threshold for positive outcome) from the N = 20 animals studied were added 
together. The injured vehicle control “spontaneous” total positive outcome rate was highly 
consistent (30%–35%) across all model-time combinations, indicating that about one-third 
of untreated animals fall above the threshold, similar to the variability in outcomes expected 
for animal models of mild-to-moderate TBI. Based on our Statistical Considerations, our 
prospective effectiveness evaluation criteria (Agent-specific evaluation metrics for screening 
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in Tier 1) dictated that we designate as candidates all CsA doses with a likelihood of having 
an underlying total positive outcome rate that is 30% more than the injured untreated vehicle 
rate (30%–35%) for that model-time “trial,” or a 60%–65% total positive outcome rate. 
Given our sample size and imposing the pharmaceutical industry standard for false-positive 
and false-negative rates in a traditional single-arm randomized clinical trial (10), this 
strategy serves to identify the required number of positive outcomes any dose must achieve 
to be considered as a candidate. The beta error accepted by the industry (<5%) ensures that 
we have a >95% chance of identifying all doses with an underlying positive outcome rate 
required by our 60%–65% Evaluation Plan threshold for effectiveness (Agent-specific 
evaluation metrics for screening in Tier 1).
All positive outcome rates are provided in Table 3. Specifically, using the pharmaceutical 
industry standard for single-arm randomized clinical trials (10) where beta error is 5%, for 
Tier 1 group sizes of 20 we accepted any dose with at least 10 positive outcome responses 
(50% experimental positive outcome rate) as being consistent with the likelihood of having 
an underlying rate of at least 65%. For the one model/time combination with a vehicle 
control positive outcome rate of 30%, our effectiveness evaluation targets an underlying rate 
of 60% as an effective dose to continue on to Tier 2, and we accept any dose with nine 
positive outcomes (45% experimental response rate) as being consistent with the likelihood 
of having an underlying rate of at least 60%.
No CsA doses in the RNR model with 1-h post-TBI delay start time were effective. One 
dose (20 mg/kg) in the RNR 6-h delay start time group and one dose (60 mg/kg) in the CCI 
1-h delay group met our criteria for effectiveness. Three doses (10, 20 and 60 mg/kg) met 
our criteria in the CCI 6-h delay group (shaded in yellow in Table 3). The same data are 
presented in a graphical format for the four dose-time study arms in Figure 3, with the 
colored vertical bars indicating total positive outcome rates for each dose, the dark 
horizontal line indicating the underlying effectiveness evaluation positive outcome rate 
threshold, the gray zone as the 5% beta error, and the bright yellow line as the positive 
outcome rate threshold that must be met to achieve our effectiveness evaluation targets with 
our small sample size and a 5% beta error. All doses at or exceeding the yellow line in 
Figure 3 meet the underlying positive outcome rate prescribed by our effectiveness 
evaluation plan (Agent-specific evaluation metrics for screening in Tier 1) and are defined 
as “successful” doses. As can be seen, several doses and administration start times met 
criteria for being promising and going on to Tier 2 testing for each injury model. Not 
surprisingly, given the convex parabolic pharmacodynamics for CsA demonstrated in rodent 
TBI treatment trials (85, 87), we often observed a narrow optimal dose range, and we did not 
observe that a linearly increasing concentration of CsA had increasingly positive therapeutic 
value.
Tier 1 dose response
Although this study was underpowered to identify dose-responses in Tier 1, we examined 
qualitative trends in dose effectiveness in either pathology or mitochondrial function in each 
injury type. First, we consider trends in dose effectiveness for each injury type, followed by 
those for each delay to initiation of treatment. Raw data of the injury volume (as a percent of 
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total brain volume) (top row, Figure 4) and mitochondrial function (bottom row) are 
provided (mean ± SE). Arrows indicate which direction is associated with improved 
outcomes. As in humans, the injury presents with a high degree of variability, even given the 
same mechanical input (head rotational velocity in RNR and cortical deformation in CCI) as 
demonstrated by standard error bars in the vehicle no-treatment groups (blue bars) for 
injured volume (top row) and mitochondrial function (bottom row).
After RNR injury, the 20 mg/kg dose (green bars, Figure 4) meets the total “positive 
outcome” effectiveness evaluation rate threshold in the 6-h delay to treatment group by 
improving both pathology and mitochondrial function. The 60 mg/kg dose (orange) in the 6-
h delay group looks promising but falls below the total positive outcome rate effectiveness 
evaluation threshold because of larger variability in the mitochondrial response at that dose. 
After CCI injury, increases in the “positive outcome” response rate with treatment tend to be 
driven by improvements in lesion volume pathology at higher CsA doses rather than dose-
related improvement in mitochondrial function in the severely compromised penumbral 
region of the cortical lesion.
Given the variability in outcomes in large animal models, it is not surprising to us that the 
qualitative therapy effect sizes appear relatively small in a large animal, limited-subject-
number trial design. Given that we can only examine trends because our study is 
underpowered to examine dose effect sizes, our data obtained in a rigorous study, with two 
injury models representing the focal and diffuse extremes along the spectrum of TBI, 
support our hypothesis that the underlying therapeutic mechanism and most effective CsA 
dose may vary with injury type, as in pheno- and geno-specific cancer therapies.
DISCUSSION
Our effectiveness evaluation criteria are ambitious: to identify CsA doses that demonstrate 
clearly demonstrable protection levels for the developing brain. For each start time and 
model combination, our goal was to identify all effective doses and select two doses to move 
forward to Tier 2: the minimum effective dose and the dose with the greatest magnitude of 
neuroprotection. If no doses for a time-model combination demonstrate effectiveness, that 
time-model combination would be designated as futile and discontinued from further study. 
Using this strategy, we found that one efficacious CsA dose qualified to move forward to 
further study in Tier 2 in each of three model-start time trials. Specifically, we find that no 
CsA doses in the RNR model with 1-h post-TBI delay start time were effective. One dose 
(20 mg/kg) in the RNR 6-h delay start time group and one dose (60 mg/kg) in the CCI 1-h 
delay group met our criteria and are worthy of study in Tier 2. Three doses (10, 20 and 60 
mg/kg) met our criteria in the CCI 6-h delay group. Consistent with our effectiveness 
evaluation plan, because the lowest dose also had the highest rate of positive outcomes, only 
that dose (10 mg/kg) would move forward for study of long-term neurofunctional outcomes. 
It is interesting to note that lower doses were more effective at longer delays to treatment (6 
h) and higher doses were more effective with more acute (1 h) post-TBI administration.
Consistent with other investigators who have reported a parabolic pharmacodynamics in 
rodent models of TBI (85, 87), we identified a narrow optimal dose range. What has been of 
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additional interest is that the results suggest that this agent may work differently in the 
different injury types, paving the way for injury-type-specific neuroprotective strategies.
As we hypothesized, we speculate that these findings may have implications for temporal 
specificity of therapeutic mechanistic targets. To inform our human trial design, we included 
two clinically relevant treatment windows (1 and 6-h delays to the initiation of 24-h 
treatment) and found that there are promising doses at both timepoints. We conclude that 
CsA has a practical, generous and promising therapeutic window. Future studies should 
investigate further why some doses were effective at 6 h and not 1 h post-TBI because this 
finding could significantly alter some of the usual assumptions about optimal timing of 
treatment of TBI.
Future preclinical animal studies should investigate the interesting underlying mechanisms 
associated with injury-specific responses, the role of treatment duration on outcome and a 
more precise dose–response curve. These studies are outside the scope of this restricted 
experimental design and our limited funding mechanism, and would require larger group 
sizes to detect the more subtle changes in outcome that occur with different injury 
mechanisms and CsA doses. It should be noted that the variability in even the most carefully 
standardized large animal models almost certainly will limit the effect sizes seen, and this 
may be a clearer reflection of what would likely occur in a human neuroprotection trial.
This is the first report of a preclinical trial paradigm to evaluate therapeutic effectiveness of 
any TBI treatment in both isolated focal and diffuse injuries, and our findings show that 
therapeutic dose level and response mechanisms vary with TBI type. These Tier 1 results 
support CsA as a potentially promising therapy for both focal and diffuse injuries in the 
immature brain that warrants further investigation to evaluate neurofunctional effectiveness. 
With funding for Tier 2 in this translational model, long-term neurofunctional outcomes 
would be evaluated after a clinically fidelic ICU experience for the promising CsA doses 
and would include naïve controls for behavior norms, uninjured anesthetized controls who 
undergo an ICU experience (with potential cognitive and behavioral impact), an injured CCI 
vehicle group and an injured RNR vehicle control group (total of seven groups, 30/group).
In conclusion, this project is the first immature large animal translational treatment trial for 
pharmacologic intervention for TBI in children. Its overall structure and milestones were 
designed specifically to parallel those used in human intervention trials in the pediatric age 
group. Because TBI is heterogeneous, the trial tests the intervention in two different injury 
types that bracket the range seen in clinical injury and uses two different times of drug 
administration and four different doses of drug. We designed our immature large animal 
model platform as a rigorous preclinical screen for a TBI intervention that overcomes some 
of the failures attributed to previous rodent trials (45) and specifically included a 
randomized blinded experimental design, careful attention to statistical considerations, data 
handling, clinically relevant conditions and efficacy testing in both diffuse and focal TBI. 
We conclude that our platform, while arduous and detailed, has proven itself as a successful 
comprehensive preclinical screen to identify potential treatments for use in patients with 
TBI.
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Figure 1. 
Schematic of two head injury models. Focal injuries produced by controlled cortical impact 
(CCI, top) and diffuse brain injuries produced by a sagittal rapid nonimpact rotation (RNR) 
of the head (bottom). Representative coronal sections shown with regions of axonal injury 
indicated with circles.
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Figure 2. 
Tier 2 porcine intensive care cerebral perfusion pressure (CPP) management strategy.
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Figure 3. 
Tier 1 overall positive outcome rates. Colored vertical bars indicating total positive outcome 
response rates for each dose, the dark horizontal line indicating the underlying effectiveness 
evaluation positive outcome rate threshold, the gray zone as the 5% beta error, and the bright 
yellow line as the response rate threshold that must be met to achieve our effectiveness 
evaluation targets with our small sample size and a 5% beta error. All doses at or exceeding 
the yellow line meet the underlying positive outcome rate prescribed by our effectiveness 
evaluation plan, and are defined as “successful” doses.
Margulies et al. Page 27
Brain Pathol. Author manuscript; available in PMC 2016 May 01.
Figure 4. 
Tier 1 CsA dose–response findings.
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Table 1
Group size determination and power considerations.
n/group Positive outcome rates Continuous measures
Controls Treated Difference 95% CI Effect size 95% CI
Total n = 20 1.0% 32.7% 31.7%
10.0% 47.9% 37.9% ±22.8% 0.82σ ±0.47σ
20.0% 62.5% 42.5%
Brain Pathol. Author manuscript; available in PMC 2016 May 01.




1-h RNR 60 60 21
6-h RNR 50 50 12
1-h CCI 60 60 17
6-h CCI 50 50 7
Total 220 220 57
Abbreviations: RNR = rapid nonimpact rotation; CCI = controlled cortical impact.
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Table 3
Tier 1 overall positive outcome rates. Dose groups that achieve the required positive outcome rate to be 
considered promising as defined by our Tier 1 effectiveness evaluation plan are shaded in yellow.
Group Outcome (Vehicle) 0 mg/kg/day 10 mg/kg/day 20 mg/kg/day 40 mg/kg/day 60 mg/kg/day
1-h RNR Pathology 4/20 0/10 1/10 2/10 0/10
Mitochondria 10/20 6/10 4/10 5/10 4/10
Total positive outcome rate 14/40 (35%) 6/20 (30%) 5/20 (25%) 7/20 (35%) 4/20 (20%)
6-h RNR Pathology 2/10 2/10 4/10 1/10 3/10
Mitochondria 5/10 7/10 6/10 5/10 6/10
Total positive outcome rate 7/20 (35%) 9/20 (45%) 10/20 (50%) 6/20 (30%) 9/20 (45%)
1-h CCI Pathology 4/20 1/10 4/10 2/10 6/10
Mitochondria 9/20 6/10 4/10 6/10 5/10
Total positive outcome rate 13/40 (33%) 7/20 (35%) 8/20 (40%) 8/20 (40%) 11/20 (55%)
6-h CCI Pathology 2/10 4/10 5/10 3/10 4/10
Mitochondria 5/10 7/10 4/10 3/10 5/10
Total positive outcome rate 6/20 (30%) 11/20 (55%) 9/20 (45%) 6/20 (30%) 9/20 (45%)
Abbreviations: RNR = rapid nonimpact rotation; CCI = controlled cortical impact.
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